TFX · Teleflex Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.99B | $3.05B | $2.97B | $2.79B | $2.81B | $2.54B |
| Cost of Revenue | $871.96M | $1.34B | $1.33B | $1.26B | $1.26B | $1.21B |
| Gross Profit | $1.12B | $1.70B | $1.65B | $1.53B | $1.55B | $1.32B |
| R&D | $144.78M | $161.67M | $154.35M | $153.82M | $130.84M | $119.75M |
| SG&A | $720.17M | $995.27M | $929.87M | $863.75M | $860.09M | $743.57M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $177.74M | $274.60M | $242.12M | $230.59M | $237.36M | $227.25M |
| Operating Income | $118.37M | $151.01M | $506.31M | $499.73M | $628.10M | $423.07M |
| Interest Expense | $100.22M | $83.54M | $85.08M | $54.26M | $56.97M | $66.49M |
| Income Tax | ($33.98M) | $5.32M | $76.44M | $83.00M | $74.35M | $21.93M |
| Net Income | ($905.64M) | $69.67M | $356.33M | $363.14M | $485.37M | $335.32M |
| EPS - Basic | ($20.30) | $1.49 | $7.58 | $7.74 | $10.38 | $7.21 |
| EPS - Diluted | ($20.25) | $1.48 | $7.53 | $7.68 | $10.23 | $7.09 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $378.56M | $290.19M | $222.85M | $292.03M | $445.08M | $375.88M |
| Accounts Receivable | $345.58M | $459.50M | $443.47M | $408.83M | $383.57M | $395.07M |
| Inventory | $404.39M | $600.13M | $626.22M | $578.51M | $477.64M | $513.20M |
| Accounts Payable | $130.20M | $141.03M | $132.25M | $126.81M | $118.24M | $102.52M |
| Current Assets | $1.94B | $1.47B | $1.41B | $1.41B | $1.43B | $1.42B |
| Total Assets | $6.95B | $7.10B | $7.53B | $6.93B | $6.87B | $7.15B |
| Current Liabilities | $762.03M | $649.36M | $606.75M | $581.49M | $680.12M | $540.03M |
| Long-term Debt | $2.54B | $1.56B | $1.73B | $1.62B | $1.74B | $2.38B |
| Total Liabilities | $3.82B | $2.82B | $3.09B | $2.91B | $3.12B | $3.82B |
| Stockholders' Equity | $3.12B | $4.28B | $4.44B | $4.02B | $3.75B | $3.34B |
| Retained Earnings | $3.15B | $4.12B | $4.11B | $3.82B | $3.52B | $3.10B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $96.68M | $638.26M | $511.68M | $342.81M | $652.14M | $437.14M |
| Investing Cash Flow | ($812.65M) | ($99.36M) | ($621.23M) | ($837.78M) | $156.74M | ($837.78M) |
| Financing Cash Flow | $611.54M | ($421.93M) | $38.54M | ($217.51M) | ($715.82M) | $455.16M |
| CapEx | $95.24M | $126.43M | $91.44M | $79.19M | $71.62M | $90.69M |
| Free Cash Flow | $1.45M | $511.83M | $420.24M | $263.62M | $580.52M | $346.45M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 56.2% | 55.9% | 55.4% | 54.9% | 55.2% | 52.2% |
| Operating margin | 5.9% | 5.0% | 17.0% | 17.9% | 22.4% | 16.7% |
| EBITDA margin | 14.9% | 14.0% | 25.2% | 26.2% | 30.8% | 25.6% |
| Net margin | -45.4% | 2.3% | 12.0% | 13.0% | 17.3% | 13.2% |
| Free cash flow margin | 0.1% | 16.8% | 14.1% | 9.4% | 20.7% | 13.7% |
| FCF / Net income | -0.00 | 7.35 | 1.18 | 0.73 | 1.20 | 1.03 |
| R&D / Revenue | 7.3% | 5.3% | 5.2% | 5.5% | 4.7% | 4.7% |
| SG&A / Revenue | 36.1% | 32.7% | 31.3% | 30.9% | 30.6% | 29.3% |
| Effective tax rate | - | 7.1% | 17.7% | 18.6% | 13.3% | 6.1% |
| Return on assets | -13.0% | 1.0% | 4.7% | 5.2% | 7.1% | 4.7% |
| Return on equity | -29.0% | 1.6% | 8.0% | 9.0% | 12.9% | 10.1% |
| Return on invested capital | 1.7% | 2.4% | 6.8% | 7.2% | 9.9% | 6.9% |
| Liquidity | ||||||
| Current ratio | 2.54 | 2.27 | 2.32 | 2.43 | 2.10 | 2.63 |
| Quick ratio | 2.01 | 1.34 | 1.29 | 1.43 | 1.40 | 1.68 |
| Cash ratio | 0.50 | 0.45 | 0.37 | 0.50 | 0.65 | 0.70 |
| Leverage | ||||||
| Debt / Equity | 0.81 | 0.36 | 0.39 | 0.40 | 0.46 | 0.71 |
| Debt / Assets | 0.37 | 0.22 | 0.23 | 0.23 | 0.25 | 0.33 |
| Debt / EBITDA | 8.58 | 3.66 | 2.31 | 2.22 | 2.01 | 3.66 |
| Interest coverage | 1.2x | 1.8x | 6.0x | 9.2x | 11.0x | 6.4x |
| Equity multiplier | 2.22 | 1.66 | 1.70 | 1.72 | 1.83 | 2.14 |
| Liabilities / Assets | 0.55 | 0.40 | 0.41 | 0.42 | 0.45 | 0.53 |
| Efficiency | ||||||
| Asset turnover | 0.29 | 0.43 | 0.39 | 0.40 | 0.41 | 0.35 |
| Inventory turnover | 2.16 | 2.24 | 2.12 | 2.18 | 2.64 | 2.36 |
| Days sales outstanding | 63d | 55d | 54d | 53d | 50d | 57d |
| Days inventory outstanding | 169d | 163d | 172d | 168d | 138d | 155d |
| Days payable outstanding | 55d | 38d | 36d | 37d | 34d | 31d |
| Cash conversion cycle | 178d | 180d | 190d | 184d | 154d | 180d |
| Valuation | ||||||
| P / E | - | 120.3x | 33.1x | 32.5x | 32.1x | 58.0x |
| P / B | 1.7x | 2.0x | 2.7x | 2.9x | 4.1x | 5.8x |
| P / S | 2.7x | 2.8x | 4.0x | 4.2x | 5.5x | 7.7x |
| EV / EBITDA | 25.7x | 22.7x | 17.8x | 18.0x | 19.5x | 33.0x |
| Growth | ||||||
| Revenue growth (YoY) | -34.6% | 2.4% | 6.6% | -0.7% | 10.7% | -2.2% |
| Revenue CAGR (3y) | -10.6% | 2.7% | 5.4% | 2.5% | 14.6% | 5.7% |
| Revenue CAGR (5y) | -4.7% | 3.3% | 9.8% | 5.4% | 8.5% | 7.0% |
| Gross profit growth (YoY) | -34.2% | 3.4% | 7.6% | -1.2% | 17.0% | -11.2% |
| Operating income growth (YoY) | -21.6% | -70.2% | 1.3% | -20.4% | 48.5% | -1.0% |
| Net income growth (YoY) | - | -80.4% | -1.9% | -25.2% | 44.7% | -27.3% |
| EPS growth (YoY) | - | -80.3% | -2.0% | -24.9% | 44.3% | -27.7% |
| EPS CAGR (3y) | - | -47.5% | 2.0% | -7.8% | 33.6% | 29.4% |
| EPS CAGR (5y) | - | -31.5% | 11.9% | 18.6% | 15.5% | 6.8% |
| FCF growth (YoY) | -99.7% | 21.8% | 59.4% | -54.6% | 67.6% | 3.6% |
| FCF CAGR (5y) | -66.6% | 8.9% | 3.5% | -5.8% | 10.2% | 7.4% |
| Book value growth (YoY) | -27.0% | -3.7% | 10.4% | 7.1% | 12.5% | 12.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.99B totalAmericas Segment$1.28B · 64.2%
EMEASegment$472.41M · 23.7%
Asia Segment$241.10M · 12.1%
Product / service
$1.99B totalVascular Access$917.73M · 46.1%
Interventional$647.79M · 32.5%
Surgical$418.15M · 21.0%
Other$9.04M · 0.5%
Geographic
$1.99B totalUS$1.18B · 59.3%
Europe$484.73M · 24.3%
Asia And Asia Pacific$218.03M · 10.9%
All Other$108.13M · 5.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.19
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing TELEFLEX INC against the 5 most active filers in the same SIC group.
Dividends
$1.36/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 22, 2026 | $0.3400 |
| Mar 6, 2026 | $0.3400 |
| Nov 14, 2025 | $0.3400 |
| Aug 15, 2025 | $0.3400 |
| May 20, 2025 | $0.3400 |
| Mar 7, 2025 | $0.3400 |
| Nov 15, 2024 | $0.3400 |
| Aug 15, 2024 | $0.3400 |
| May 14, 2024 | $0.3400 |
| Feb 29, 2024 | $0.3400 |
| Nov 14, 2023 | $0.3400 |
| Aug 14, 2023 | $0.3400 |
| May 12, 2023 | $0.3400 |
| Mar 2, 2023 | $0.3400 |
| Nov 14, 2022 | $0.3400 |
| Aug 12, 2022 | $0.3400 |
| May 13, 2022 | $0.3400 |
| Mar 4, 2022 | $0.3400 |
| Nov 12, 2021 | $0.3400 |
| Aug 13, 2021 | $0.3400 |
| May 13, 2021 | $0.3400 |
| Mar 4, 2021 | $0.3400 |
| Nov 12, 2020 | $0.3400 |
| Aug 13, 2020 | $0.3400 |